560P Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC

C. Weng, K. Tang,S. Jin, C. Zhou, Y. Yao, J-W. Su,H. Chen, K. Liu, Y. Li, J. Yang

Annals of Oncology（2023）

Cited 0|Views0

No score

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined